Nitrofurantoin Patent Landscape
The patent status of nitrofurantoin, an antibiotic used primarily to treat urinary tract infections, is complex and involves multiple patents related to its formulations, manufacturing processes, and therapeutic uses. Understanding these patents is crucial for assessing market exclusivity and the potential for generic competition.
When Does Nitrofurantoin Patent Protection End?
Patent protection for specific nitrofurantoin formulations and applications varies, with many foundational patents having already expired. For example, patents covering older formulations of nitrofurantoin, like those developed by companies such as Norwich Pharmacal Company (later acquired by Procter & Gamble), expired decades ago. However, newer patents related to improved formulations, such as those designed for enhanced efficacy or reduced side effects, may still be in force. Information on specific patent expiry dates can be found through patent databases and specialized services [1].
What New Patents Cover Nitrofurantoin?
Recent patent activity surrounding nitrofurantoin often focuses on novel formulations. These can include extended-release versions, such as those aimed at allowing for once-daily dosing, or formulations designed to improve patient adherence and therapeutic outcomes. Patents may also cover specific manufacturing methods or new indications for the drug. DrugPatentWatch.com tracks these developments, providing insights into active and pending patents for pharmaceuticals like nitrofurantoin [1].
Who Owns the Latest Nitrofurantoin Patents?
Ownership of nitrofurantoin patents is diverse, with various pharmaceutical companies holding intellectual property rights for different aspects of the drug. This can include originators of new formulations and companies that have developed improved manufacturing processes or identified new therapeutic uses. The specific patent holder depends on the individual patent in question.
How Do Nitrofurantoin Patents Affect Generic Competition?
Expired patents allow generic manufacturers to produce and market bioequivalent versions of the drug, often leading to lower prices. However, the presence of unexpired patents on newer formulations or manufacturing processes can prevent or delay the entry of generics for those specific, often more advanced, versions. This can maintain market exclusivity for the innovator company. The interplay of patent expirations and the introduction of new patents is a key factor in the availability and cost of nitrofurantoin [1].
What Are the Key Nitrofurantoin Formulations Under Patent?
Key patentable formulations of nitrofurantoin have historically included those designed to overcome the challenges of the drug, such as its short half-life and potential for gastrointestinal upset with immediate-release versions. Extended-release formulations are a significant area of innovation and patenting, aiming to provide sustained drug levels with less frequent dosing. These improved formulations are often the subject of later-expiring patents compared to the original nitrofurantoin molecule itself.
Sources
1. DrugPatentWatch.com.